The abstract is read at the publisher; the summary is JClub's.
iPSC-derived CAR macrophages targeting Glypican-3 for hepatocellular carcinoma show enhanced inflammatory and phagocytic programs when engineered with ID3 endowment and TGFBR2 deletion.
- Why it matters: Solid-tumor CAR T approaches are constrained by limited infiltration and immunosuppression, motivating macrophage designs that resist suppressive signaling while remaining effective in vivo.
- What they did: The team used single-cell RNA sequencing to link ID3 endowment and TGFBR2 deletion to altered transcriptional programs, then tested labeled CAR-iMac in orthotopic HCC models with MPI tracking, histology, and transcriptional profiling.
- The result: An optimized dose regimen produced antitumor activity and preliminary safety in humanized mice, inhibited patient-derived xenograft growth, and improved tumor killing with patient-matched T cells in patient-derived HCC organoids.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.